ID   MIA PaCa-2 GR300
AC   CVCL_WI24
SY   MiaPaCa-2 GR300
DR   cancercelllines; CVCL_WI24
DR   Wikidata; Q95989682
RX   PubMed=25485960;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0428 ! MIA PaCa-2
SX   Male
AG   65Y
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 05-10-23; Version: 9
//
RX   PubMed=25485960; DOI=10.4161/15384047.2014.986967;
RA   Samulitis B.K., Pond K.W., Pond E., Cress A.E., Patel H., Wisner L.,
RA   Patel C., Dorr R.T., Landowski T.H.;
RT   "Gemcitabine resistant pancreatic cancer cell lines acquire an
RT   invasive phenotype with collateral hypersensitivity to histone
RT   deacetylase inhibitors.";
RL   Cancer Biol. Ther. 16:43-51(2015).
//